Rakovina Therapeutics Chief Scientific Officer Mads Daugaard joined Steve Darling from Proactive to share news the company has been given a funding from the National Research Council of Canada Industrial Research Assistance Program. Daugaard telling Proactive the non-dilutive financing will provide its scientists in the development of DNA-damage response inhibitors with the goal of selecting one or more lead compounds for advancement to either toxicology and/or investigational new drug studies.
Rakovina Therapeutics receives government grant to accelerate novel cancer therapy program
